LONG-LIFENCT07719088
Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Dec 2026 to Nov 16, 2026
- Site details revised
- Notable Primary endpoints: details revised at 1 of 2 entries
- Eligibility criteria expanded, about 5 words
- Secondary endpoints: details revised at 6 of 8 entries
- Minor Secondary endpoints: details revised at 5 of 8 entriesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Participants in this arm will receive one 25mg dose of psilocybin paired with therapeutic support.
Participants in this arm will receive two 25mg doses of psilocybin approximately 4 weeks apart paired with therapeutic support.
Participants in this arm will receive three 25mg doses of psilocybin approximately 4 weeks apart paired with therapeutic support.
Participants in this arm will not receive psilocybin as part of the main study but will be given the opportunity to receive a single 25mg dose of psilocybin with therapeutic support after their study participation is complete.
Drugs: Psilocybin (Usona Institute)
Sites
1 site in 1 country
- Vail Health Behavioral HealthEdwards, Colorado, United States